Physician profile
Andrew David Wright
NPI 1346260361
$8,412.58
in general payments reported to CMS, 2019-2025
51 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $472 · 2021: $852 · 2022: $1,721 · 2023: $2,792 · 2024: $911 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Travel and Lodging: $968 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.32 |
| Travel and Lodging | $968.00 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $1,816.34 | 2022-2023 | |
| Astellas Pharma US INC | $1,050.54 | 2019-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $552.06 | 2019-2025 | Botox, Lupron Depot |
| Dendreon Pharmaceuticals LLC | $434.90 | 2019-2023 | Provenge |
| Janssen Biotech, INC. | $413.69 | 2019-2024 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $344.73 | 2019-2025 | |
| Antares Pharma, INC. | $264.53 | 2019-2025 | Xyosted |
| Blue Earth Diagnostics | $242.52 | 2019-2025 | Posluma |
| Progenics Pharmaceuticals, INC. | $223.78 | 2021-2024 | Pylarify |
| Procept Biorobotics Corporation | $207.58 | 2022-2025 | Aquabeam System |
| Travere Therapeutics, INC. | $206.67 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $186.67 | 2019-2022 | |
| Angiodynamics, INC. | $157.08 | 2022 | |
| Teleflex LLC | $156.71 | 2021-2025 | Urolift |
| Novartis Pharmaceuticals Corporation | $141.90 | 2023-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $140.22 | 2019-2024 | Spaceoar System |
| Axonics, INC. | $135.94 | 2022-2024 | Bulkamid |
| Sumitomo Pharma America, INC. | $134.94 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $130.73 | 2021-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $116.92 | 2021-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $115.94 | 2021-2024 | Lynparza |
| Tolmar, INC. | $99.66 | 2023-2025 | Jatenzo, Eligard |
| C. R. Bard, INC. & Subsidiaries | $93.94 | 2023 | Bard Urinary Drainage Bag |
| 180 Medical, INC. | $92.79 | 2020-2024 | Gentlecath |
| Urogen Pharma, INC. | $76.24 | 2024-2025 | |
| Rochester Medical Corporation | $75.99 | 2022 | |
| Convatec INC. | $65.56 | 2020-2024 | |
| Olympus America INC. | $52.87 | 2019-2025 | Itind System |
| Myovant Sciences INC. | $52.39 | 2021-2022 | |
| Coloplast Corp | $51.90 | 2019-2023 | Speedicath |
| Becton, Dickinson and Company | $51.84 | 2023 | Bard Urinary Drainage Bag |
| Pfizer INC. | $51.09 | 2019-2022 | |
| Hollister Incorporated | $48.51 | 2021 | |
| Endo Pharmaceuticals INC. | $47.51 | 2019-2020 | |
| Halozyme INC | $40.36 | 2023 | |
| Therapeuticsmd, INC. | $36.68 | 2019 | |
| Neotract INC. | $32.70 | 2020 | |
| Allergan, INC. | $29.52 | 2020-2021 | |
| Immunitybio, INC. | $29.35 | 2025 | |
| Urovant Sciences INC | $28.77 | 2021-2022 | |
| Cook Medical LLC | $27.03 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $20.98 | 2019 | |
| Ambu INC. | $20.10 | 2024 | |
| Calyxo, INC. | $19.15 | 2024 | Cvac Aspiration System |
| Sun Pharmaceutical Industries INC. | $18.70 | 2019 | |
| Amgen INC. | $16.56 | 2019 | |
| Biotissue Holdings INC. | $16.49 | 2023 | |
| Clarus Therapeutics INC. | $15.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.96 | 2022 | |
| Zyla Life Sciences, INC. | $12.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.